Cargando…

Erythropoietin stimulating agents in the management of anemia of chronic kidney disease

Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayat, Amir, Haria, Dhiren, Salifu, Moro O
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769266/
https://www.ncbi.nlm.nih.gov/pubmed/19920963
_version_ 1782173558212919296
author Hayat, Amir
Haria, Dhiren
Salifu, Moro O
author_facet Hayat, Amir
Haria, Dhiren
Salifu, Moro O
author_sort Hayat, Amir
collection PubMed
description Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.
format Text
id pubmed-2769266
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-27692662009-11-17 Erythropoietin stimulating agents in the management of anemia of chronic kidney disease Hayat, Amir Haria, Dhiren Salifu, Moro O Patient Prefer Adherence Review Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD. Dove Medical Press 2008-02-02 /pmc/articles/PMC2769266/ /pubmed/19920963 Text en © 2008 Hayat et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Hayat, Amir
Haria, Dhiren
Salifu, Moro O
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title_full Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title_fullStr Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title_full_unstemmed Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title_short Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
title_sort erythropoietin stimulating agents in the management of anemia of chronic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2769266/
https://www.ncbi.nlm.nih.gov/pubmed/19920963
work_keys_str_mv AT hayatamir erythropoietinstimulatingagentsinthemanagementofanemiaofchronickidneydisease
AT hariadhiren erythropoietinstimulatingagentsinthemanagementofanemiaofchronickidneydisease
AT salifumoroo erythropoietinstimulatingagentsinthemanagementofanemiaofchronickidneydisease